Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reglan exclusivity

Executive Summary

Robins' I.V. formulation of metoclopramide lost exclusive labeling for chemotherapy- and cisplatin-induced emesis and diabetic gastroparesis on Sept. 24, 1986. "The Pink Sheet" (Oct. 20, "In Brief") erroneously said exclusivity for the indications did not expire until December 1987. Robins did, however, recently obtain a patent covering the method of controlling emesis caused by cisplatin and cancer chemotherapy. That patent, which expires in August 2002, is the only patent in force on Reglan.

You may also be interested in...



Health And Wellness Trademark Review 12 January, 2021

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Cosmetic And Personal Care Trademark Review 12 January, 2021

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

COVID-19 Vaccine Dosing: Pharma Says Follow The Science As It Gathers Data

The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel